OZGEN, U., S. O. SENER, Karel ŠMEJKAL, Jiří VÁCLAVÍK, D. F. SENOL, Orhan I ERDOGAN, Emil ŠVAJDLENKA, A. C. GOREN and Milan ŽEMLIČKA. Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of Lysimachia verticillaris L. and Isolation of the Major Compounds. TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES. CANKAYA-ANKARA: TURKISH PHARMACISTS ASSOC, 2020, vol. 17, No 5, p. 528-534. ISSN 1304-530X. Available from: https://dx.doi.org/10.4274/tjps.galenos.2019.71598.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of Lysimachia verticillaris L. and Isolation of the Major Compounds
Authors OZGEN, U., S. O. SENER, Karel ŠMEJKAL (203 Czech Republic, belonging to the institution), Jiří VÁCLAVÍK (203 Czech Republic, belonging to the institution), D. F. SENOL, Orhan I ERDOGAN, Emil ŠVAJDLENKA (203 Czech Republic, belonging to the institution), A. C. GOREN and Milan ŽEMLIČKA (203 Czech Republic, belonging to the institution).
Edition TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, CANKAYA-ANKARA, TURKISH PHARMACISTS ASSOC, 2020, 1304-530X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Turkey
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14160/20:00118239
Organization unit Faculty of Pharmacy
Doi http://dx.doi.org/10.4274/tjps.galenos.2019.71598
UT WoS 000585327200011
Keywords in English Anticholinesterase; HPLC; isolation; Lysimachia; tyrosinase
Tags rivok, ÚPL
Tags International impact, Reviewed
Changed by Changed by: Mgr. Hana Hurtová, učo 244985. Changed: 24/2/2021 08:03.
Abstract
Objectives: The scope of the present study was to specify the therapeutic potential for neurodegenerative diseases through evaluating cholinesterase and tyrosinase (TYR) inhibitory and antioxidant activity of Lysimachia verticillaris (LV), and to isolate the major compounds considering the most active fraction. Materials and Methods: The methanol extract (ME) of LV and the chloroform, ethyl acetate (EtOAC), and aqueous fractions obtained from it were used for biological activity and isolation studies. The ME and all fractions were tested for their acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and TYR inhibitory and antioxidant potentials using ELISA microtiter assays. Seven major compounds were isolated from the active EtOAC fraction by semi-preparative high performance liquid chromatography. The structures of the compounds were elucidated by several spectroscopic methods. Results: Marked AChE inhibitory activity was observed in the EtOAC fraction (6337 +/- 1.74%), BChE inhibitory activity in the ME and EtOAC fraction (85.84 +/- 3.01% and 83.82 +/- 3.93%), total phenol content in the EtOAC fraction (261.59 +/- 3.95 mg equivalent of gallic acid/1 g of extract) and total flavonoid contents in the EtOAC fraction (515.54 +/- 2.80 mg equivalent of quercetin/1 g of extract), and 2,2-diphenyl-1-picrylhydrazyl radical scavenging activity and ferric-reducing antioxidant power values in the aqueous and EtOAC fractions (92.54 +/- 0.67%, 92.11 +/- 0.30%; 2.318 +/- 0.054, 2.224 +/- 0.091, respectively). Accordingly, the isolation studies were carried out on the EtOAC fractions. Compounds 1-7 (gallic acid, (+)-catechin, myricetin 3-O-arabinofuranoside, myricetin 3-O-alpha-rhamnopyranoside, quercetin 3-O-beta-glucopyranoside, quercetin 3-O-arabinofuranoside, and quercetin 3-O-alpha-rhamnopyranoside, respectively) were isolated from the active EtOAC fraction. Conclusion: LV may be a potential herbal source for treatment of neurodegenerative diseases based on its strong antioxidant activity and significant cholinesterase inhibition similar to that of the reference.
PrintDisplayed: 1/9/2024 00:02